Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7222478 | 0.90 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL7222252 | 0.89 | CRHR1 (0.69) | CRHR1TDP1 | |
| SCHEMBL8062659 | 0.84 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL226802 | 0.82 | CRHR1 (0.77) | CRHR1TDP1 | |
| SCHEMBL8619340 | 0.80 | CRHR1 (0.79) | CRHR1TDP1 | |
| SCHEMBL7676276 | 0.80 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL7684798 | 0.78 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL7677531 | 0.77 | CRHR1 (0.53) | CRHR1TDP1 | |
| SCHEMBL7217519 | 0.76 | CRHR1 (0.53) | CRHR1TDP1 | |
| SCHEMBL7783147 | 0.75 | CRHR1 (0.53) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111490-A1 | Certain pyrrolopyridine derivatives: novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 2002-08-15 | — | — | US | claimed |
| US-6355651-B1 | AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | claimed |
| US-5955613-A | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1999-09-21 | — | — | US | claimed |
| WO-1998045295-A1 | CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-10-15 | — | — | WO | claimed |
| US-6670371-B2 | Antagonists of Corticotropin-Releasing Factor | NEUROGEN CORPORATION | 2003-12-30 | — | — | US | disclosed |
| US-6355651-B1 | AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-5955613-A | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands | NEUROGEN CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| WO-1998045295-A1 | CERTAIN PYRROLOPYRIDINE DERIVATIVES; NOVEL CRF1 SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111490-A1 | Certain pyrrolopyridine derivatives: novel CRF1 specific ligands | CRHR1, CRH, CRHR2 | CRHR1 1/4885TDP1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.